🔗 Share this article

As America continues making unprecedented revisions to its vaccine schedules, a particular individual appears somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who initially gained attention by casting doubt on Covid shots in the global health crisis and has zeroed in on alleged deaths following Covid immunization in her brief tenure at the FDA.

Scheduled Shifts to Pediatric Vaccine Program

Agency leaders were set to unveil major revisions to the pediatric immunization program recently, synchronizing the US with Denmark’s immunization schedule, sources say – a major change that would put the US out of step with much of the global community with no evidence for public health gain. This reveal has been delayed until the next year.

Instead of the top vaccines chief, Høeg is set to present at the meeting. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the office this calendar year.

A New Direction at the FDA

Høeg's temporary position might represent a strengthened alliance between the drug and vaccine centers as Dr. Høeg and Prasad solidify control at the FDA – and it signals a increased emphasis upon rolling back already-approved immunizations at the FDA.

Høeg has repeatedly called for discontinuing some pediatric immunization guidelines in the US so as to align more similar to Denmark, a country with universal health coverage and a citizenry roughly the size of the state of Wisconsin.

So far comments, she has kept her attention on vaccination policy – traditionally the responsibility of Prasad, head of the FDA’s vaccine center – instead of medication approval.

Questions Over Qualifications

The appointee has no obvious experience in drug development, regulation or administrative roles, which has been customary for former heads of the CBER. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“It seems she lacks to have the requisite experience” for running the drug-regulation department, stated a neurologist and psychiatrist. “She lacks experience running a scientific study. She is not versed in managing a major agency. She lacks background in drug approvals.”

Former heads of CBER would “be deeply familiar with regulatory frameworks and the science of drug development”, said a former acting FDA commissioner. “Objectively, she doesn’t have the kind of background that former directors who ran the center have had.”

The drug center has an vast workload at the agency, she emphasized.

“The public just zeroes in on the innovative therapies, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There’s a biologic copycat branch, OTC medication office and more, and every single one must be looked after,” Dr. Woodcock noted. “The thing you neglect, that is the part that I always told people is going to bite you.”

Furthermore, a major management component to the position, which supervises in excess of 5,000 personnel. “It is a massive administrative position, if you perform it correctly,” the former official said.

Official Statement and Controversial Programs

When asked about inquiries about Dr. Høeg's fitness for the role and whether this appointment indicates increased cooperation among regulatory chiefs on immunizations, a representative responded that the “questions are based on inaccurate premises”.

“This background matches the functions of her position,” the spokesperson stated, citing the period Høeg spent counseling the agency head on “pharmaceutical safety and approval science, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the agency head's new fast-track approval initiative, a controversial one-day medication authorization process that reportedly troubled her preceding directors. “By what process are these therapies being picked for this fast-track system? Who is making the calls?” Howard said. “There’s a lot of secrecy happening at the agency right now.”

Overall, he stated, “the FDA looks to be trending towards more relaxed oversight of pharmaceuticals, with the exception of vaccines.”

Public Track Record on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if problematic, track record, Howard said. She authored a study using unconfirmed volunteer-provided data to assess the frequency of myocarditis following COVID-19 immunization. She consulted for the Florida top health official Joseph Ladapo, who reportedly have changed statistics to suggest Covid vaccines are more dangerous than they are.

Among her “wish list” for the new administration featured changing rules for recently developed shots and ending “non-essential” vaccines, she stated following the vote on a audio program. At the agency, Høeg has according to sources floated the idea of barring adolescent males from obtaining Covid vaccinations.

“She’s an thorough dogmatist who commences with her conclusions and works backwards to fit the science in a extremely disingenuous, dishonest manner,” Howard argued.

Taking Control and a “Revenge Tour”

Høeg joined fellow contrarians, {like|